Latest Insights on ABBV
Profit From AbbVie’s Struggles TodayAbbvie’s flagship medication Humira is a huge seller in the U.S. and abroad. But as more companies develop their own versions, will Abbvie’s stock crater in the face of tighter competition? I’ll review Abbvie’s balance sheet and fundamentals to let you know whether you should expect the stock to surge — or fall even further in 2020.
No Fear Here: 4 Stocks to Beat the Wuhan VirusFriday Four Play: The “Fear Inoculum” Edition (Did a friend forward you this email? If so, you owe them big-time! Seriously, this is Great Stuff. We don’t take that title lightly. After you’ve thanked your friend profusely, why not sign up for yourself today? It’s mostly painless. I promise.) The Wuhan coronavirus is officially a […]
Google Won’t Forget You … Ever; Snap Hands Over Project Voldemort
September 24, 2019 Great StuffGone, but Never Forgotten Today, we’re going to talk about digital privacy. It’s not a sexy topic by any means. But it’s a vitally important one. Earlier today, Europe’s highest court ruled in favor of Alphabet Inc.’s (Nasdaq: GOOG) Google. The case centered on Google users’ “right to be forgotten.” At its core, “right to […]
Friday Four Play: Good Jobs = Bad News
July 5, 2019 Great StuffThat was quite the Fourth of July celebration, wasn’t it? The fireworks, the music … and stuff. Freedom was everywhere. It was awesome. I don’t know about you, but I’m beat this morning. Apparently, so is the market. But we’ll get to that in a minute. Next week, I’m going on vacation to celebrate my […]
The Trade War Truce Rally: AMD, Apple, Nvidia and Oil?
July 1, 2019 Great StuffToday’s G-20 rally is no surprise. There was no way President Donald Trump was coming out of the G-20 meeting without a win — one way or another. And he certainly got a win. I’m not talking about the pause in the trade war — that was a given. It fits Trump’s M.O. to a […]